KROS Quote, Financials, Valuation and Earnings

Innoviva, Inc. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of 80.81%. Keros Therapeutics, Inc.'s return on equity of 9.94% beat Innoviva, Inc.'s return on equity of 17.06%.

Keros Therapeutics, Inc. has a consensus price target of $23.38, signalling upside risk potential of 11.15%. On the other hand Innoviva, Inc. has an analysts' consensus of $32.50 which suggests that it could grow by 64.14%. Given that Innoviva, Inc. has higher upside potential than Keros Therapeutics, Inc., analysts believe Innoviva, Inc. is more attractive than Keros Therapeutics, Inc..

Keros Therapeutics, Inc. has a beta of 0.892, which suggesting that the stock is 10.815% less volatile than S&P 500. In comparison Innoviva, Inc. has a beta of 0.471, suggesting its less volatile than the S&P 500 by 52.903%.

Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. Innoviva, Inc. pays out -- of its earnings as a dividend.

Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are smaller than Innoviva, Inc. quarterly revenues of $111.3M. Keros Therapeutics, Inc.'s net income of -$7.3M is lower than Innoviva, Inc.'s net income of $89.9M. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 13.63x while Innoviva, Inc.'s PE ratio is 14.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 3.46x versus 3.89x for Innoviva, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of 31.72%. Keros Therapeutics, Inc.'s return on equity of 9.94% beat Eli Lilly & Co.'s return on equity of 106.26%.

Keros Therapeutics, Inc. has a consensus price target of $23.38, signalling upside risk potential of 11.15%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.44%. Given that Keros Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Keros Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Keros Therapeutics, Inc. has a beta of 0.892, which suggesting that the stock is 10.815% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Keros Therapeutics, Inc.'s net income of -$7.3M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 13.63x while Eli Lilly & Co.'s PE ratio is 53.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 3.46x versus 16.54x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen, Inc. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of -1144.46%. Keros Therapeutics, Inc.'s return on equity of 9.94% beat Ocugen, Inc.'s return on equity of -345.08%.

Keros Therapeutics, Inc. has a consensus price target of $23.38, signalling upside risk potential of 11.15%. On the other hand Ocugen, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 538.3%. Given that Ocugen, Inc. has higher upside potential than Keros Therapeutics, Inc., analysts believe Ocugen, Inc. is more attractive than Keros Therapeutics, Inc..

Keros Therapeutics, Inc. has a beta of 0.892, which suggesting that the stock is 10.815% less volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 4.540, suggesting its more volatile than the S&P 500 by 354.007%.

Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.

Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are larger than Ocugen, Inc. quarterly revenues of $1.8M. Keros Therapeutics, Inc.'s net income of -$7.3M is higher than Ocugen, Inc.'s net income of -$20.1M. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 13.63x while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 3.46x versus 77.39x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of 21.32%. Keros Therapeutics, Inc.'s return on equity of 9.94% beat Pfizer Inc.'s return on equity of 10.84%.

Keros Therapeutics, Inc. has a consensus price target of $23.38, signalling upside risk potential of 11.15%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.08%. Given that Pfizer Inc. has higher upside potential than Keros Therapeutics, Inc., analysts believe Pfizer Inc. is more attractive than Keros Therapeutics, Inc..

Keros Therapeutics, Inc. has a beta of 0.892, which suggesting that the stock is 10.815% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.86% to investors and pays a quarterly dividend of $0.43 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Keros Therapeutics, Inc.'s net income of -$7.3M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 13.63x while Pfizer Inc.'s PE ratio is 14.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 3.46x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.